1. Medtech Insight

iCAD Touts PMA-Approved Tool As Time-Saver For 3D Breast Assessment

 
• By Sue Darcey

iCAD won US FDA approval for its PowerLook Tomo Detection computer-aided detection tool for the growing field of digital breast 3D tomosynthesis product. It's intended to address a key complaint by radiologists with tomosynthesis: the long time it takes to read 3D, compared to 2D exams.

US FDA approved iCAD Inc.'s PMA for its PowerLook Tomo Detection solution for breast tumor detection March 24. The firm says the product is the first ever concurrent-read computer aided detection (CAD) solution for digital breast tomosynthesis (DBT).

Current CAD systems are generally designed to analyze images from 2D mammography systems, which typically produce a total for four images per exam, after a scan. That approach has caused some frustration for radiologists who have adopted 3D tomosynthesis, which can product hundreds of images, because of the significantly longer read time

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Oncology

More from Device Area

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Danaher Faces $350M Tariff Hit, But Says It’s Ready To Absorb The Blow

 
• By Shubham Singh

Despite Danaher’s confident outlook, the company acknowledged near-term profitability fluctuations, particularly in the second quarter. Matt McGrew, Danaher’s CFO, clarified during the company’s first-quarter earnings call on 22 April, that expected operating margin softness in the second quarter – forecast at 25.5% – was not related to tariffs, but to seasonal dynamics in its respiratory diagnostics business.

Axoft Starts Commercializing Soft BCI-Enabling Materials For R&D Use, Aims To Rewrite BCI Playbook

 
• By Marion Webb

After publishing encouraging results from first-in-human trials of its brain-computer interface, Axoft announced plans to sell its BCI-enabling material Fleuron to researchers and private organizations for R&D use. The company sees this as a revenue stream and feedback loop to refine its BCI platform designed for safer, longer-lasting brain implants.